Natixis’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Natixis’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-491,724	Closed	-$1.09M	–	1163
2023 Q2	$1.09M	Buy	+491,724	New	+$1.02M	0.01%	522
2023 Q1	–	Sell	-29,006	Closed	-$54.2K	–	1248
2022 Q4	$54.2K	Buy	+29,006	New	+$72.3K	﹤0.01%	920

Natixis's PRTK Position: Q3 2023 in Review

Natixis sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 491,724 shares — an estimated $1.09M sold.

Natixis first reported a position in PRTK in Q4 2022 and held it in 2 quarters. The position peaked at $1.09M in Q2 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Natixis reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Natixis sold 491,724 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.09M.
Natixis first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
Natixis's Paratek Pharmaceuticals, Inc. position peaked at $1.09M in Q2 2023.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Natixis's 13F filing for Q3 2023, filed 14 Nov 2023.